About us
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed
Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics
Yuflyma receives approval by US FDA
41-13 Nonhyeon-dong, Gangnam-gu, Seoul, South Korea
+82 111-1234-1254
© PULIP COMMUNICATIONS Co., Ltd